MedTrace Logo

Study on Continuous Intravenous of Unfractionated Heparin (UFH) to Treat Progressive Cerebral Infarction

NCT01378000 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2019-04-30

No results posted yet for this study

Summary

A clinical trial to study the effects of dosage, infusion methods and complications of unfractionated heparin (UFH) treating acute progressive cerebral infraction was conducted. In this study, we observed the effects of four UFH treatments on 480 acute progressive cerebral infraction patients during from the 6th and the 72nd hour after the attack. It was concluded that the ultra-slow continuous intravenous infusion of UFH can significantly reduce the neurological deficit score of patients with progressive cerebral infarction, increase the cure rate, decrease the recurrence rate, and improve long-term quality of daily life. It is more effective than the treatment of intravenous infusion of low- molecular- weight UFH at once a day, and the risk of bleeding may not necessarily be increased.

Conditions

  • Heparin Causing Adverse Effects in Therapeutic Use
  • Heparin-induced Thrombosis
  • Acute Cerebral Ischemia

Sponsors & Collaborators

  • Agency for Science, Technology and Research

    collaborator OTHER

  • Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine

    lead OTHER

Principal Investigators

  • wang zh yong, professor · cangzhou hospital

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01378000 on ClinicalTrials.gov